Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.51 |
| ▸ | CDC25B | P30305 | 7/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.51 |
| ▸ | TACR2 | P21452 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898371 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL17766609 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15968116 | 1.00 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL18482843 | 0.89 | NT5E (0.52) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL20473791 | 0.89 | NT5E (0.52) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6303776 | 0.87 | TACR2 (0.48) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL20473776 | 0.87 | PTPN1 (0.50) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL28516241 | 0.87 | PTPN1 (0.50) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6303407 | 0.87 | TSHR (0.49) | NT5EPTPN1CDC25BTACR2 | |
| SCHEMBL26899483 | 0.86 | NT5E (0.49) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1520583-B1 | NKT cell-activating agents containing alpha-glycosylceramides | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1018548-B1 | CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING ALPHA-GLYCOSYLCERAMIDE | KIRIN BREWERY (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1520583-A2 | NKT cell-activating agents containing alpha-glycosylceramides | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-04-06 | — | — | EP | disclosed |
| EP-0988860-B1 | Use of a-glycosylceramides for the manufacture of a therapeutic agent for autoimmune diseases | KIRIN BREWERY (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6747010-B2 | THERAPY FOR AUTOIMMUNE DISEASE, ANTIULCER AGENTS, BRAIN DISORDERS, INDUCTION ABORTION; NATURAL KILLER CELLS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20030139351-A1 | NKT cell-activating agents containing alpha-glycosylceramides | KIRIN BEER KABUSHIKI KAISHA | 2003-07-24 | — | — | US | disclosed |
| US-6555372-B1 | Viricides and antitumor agents | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-6531453-B1 | Activating human NKT cell by culturing in vitro mononuclear cell fraction comprising human NKT cell in presence of specified compound or salt or solvate thereof | KIRIN BEERA KABUSHIKI KAISHA (JP) | 2003-03-11 | — | — | US | disclosed |
| EP-1018548-A1 | CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING $g(a)-GLYCOSYLCERAMIDE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0988860-A1 | NKT CELL ACTIVATORS CONTAINING $g(a)-GLYCOSYLCERAMIDES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139351-A1 | NKT cell-activating agents containing alpha-glycosylceramides | UGCG, NFATC1, GBA1 | NT5E 1341/4885PTPN1 3489/4885CDC25B 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.